Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2024-05-06 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Board Meeting — BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 14-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Year…
Regulatory Filings
2024-05-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification to the stock exchange about a forthcoming Board Meeting scheduled for May 14, 2024. The agenda includes consideration and approval of the Financial Results and Auditor Report for the financial year ended March 31, 2024. The document also mentions compliance with SEBI regulations and insider trading restrictions. The document is short (1810 characters) and serves as an intimation or announcement rather than containing the actual financial results or auditor report. Therefore, it is an announcement related to a board meeting and financial results approval, not the report itself. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-05-06 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialisation of securities for the quarter ended 31st March 2024. It is a compliance confirmation letter from Link Intime India Pvt. Ltd. to the company Beta Drugs Limited. The document does not contain financial statements, management discussion, or any report data. It is a regulatory compliance confirmation, not a financial report or announcement of voting results, capital changes, or other categories. Given its nature as a certification/confirmation letter related to regulatory compliance, it fits best under Regulatory Filings (RNS). The document length is short (1856 characters), and it is not an announcement of a report publication but a compliance confirmation.
2024-04-09 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the National Stock Exchange of India Limited, informing about the closure of the trading window for insiders due to the upcoming declaration of audited financial results for the fiscal year ending 31st March 2024. It references SEBI regulations and the company's code for prevention of insider trading. The document is short (1289 characters) and serves as an announcement or intimation rather than containing any financial data or the actual financial results. Therefore, it is not an Annual Report, Earnings Release, or any detailed financial report. It is an official regulatory communication related to trading restrictions, fitting best under Regulatory Filings (RNS).
2024-03-29 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialisation of securities for the quarter ended 31st December 2023. It is a compliance confirmation letter from Link Intime India Pvt. Ltd. to the company Beta Drugs Limited. The document does not contain financial statements, management discussion, or any report data. It is a regulatory compliance confirmation related to securities dematerialisation, which fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and does not fit other specific categories.
2024-01-08 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (80 characters) and contains only a digital signature with a date, without any substantive content or financial data. There is no indication of a report, announcement, or detailed filing. This matches the criteria for a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2023-12-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.